Join us at the Immuno-Oncology Summit where we convene to advance our understanding of the immune system, propelling the development of next-generation immunotherapies to optimize patient treatment outcomes.
Immuno-Oncology Summit 2025 205 days left Connecting the Immunotherapy Community to Drive Innovation and Collaboration Dates: Monday, August 11, 2025 - Wednesday, August 13, 2025 Venue: Philadelphia, Philadelphia PA, United StatesOver the past 10 years, CHI's Immuno-Oncology Summit has become ...
CHI’s Immuno-Oncology Summit Europe returns to London for 3 days of discussions and networking around the recent advances in immuno-oncology therapies.
The Immuno-Oncology Summit Brochure 2024 The Immuno-Oncology Summit Brochure 2023 The Immuno-Oncology Summit Brochure 2022 The Immuno-Oncology Summit Brochure 2021 The Immuno-Oncology Summit Brochure 2019 The Immuno-Oncology Summit Partnering Brochure 2019 ...
Did you receive a conference brochure?YesNo If yes, what is the Key Code on the label? Keycode:ex. I860F1 or F30 Group Discounts are Available! Have your colleagues or entire team attend the Immuno-Oncology Summit Europe In-Person or Virtually. Purchase a full price registration on theIndi...
Don't miss the opportunity to learn about Next-Generation CARs, TILs, and TCRs at Immuno-Oncology Summit Europe. Be part of the future of cancer treatment.
The The Immuno-Oncology Summit by Cambridge Healthech Institute Inc. app, powered by Pathable, will help you network with other attendees, interact with our spe…
vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º “IO360º” premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York Ma...
Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types....
Vivek KamathLongdom Publishing S.L